From bench to bedside: a case of rapid reversal of bortezomib-induced neuropathic pain by the TRPM8 activator, menthol.
Colvin
Leslie A
LA
Johnson
Peter R E
PR
Mitchell
Rory
R
Fleetwood-Walker
Susan M
SM
Fallon
Marie
M
D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001897:Boronic Acids / Q000009:adverse effects*; D000069286:Bortezomib; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008610:Menthol / Q000008:administration & dosage*; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D010146:Pain / Q000139:chemically induced* / Q000188:drug therapy*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D011480:Protease Inhibitors / Q000009:adverse effects; D011719:Pyrazines / Q000009:adverse effects*; D050053:TRPM Cation Channels / Q000187:drug effects
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011480:Protease Inhibitors; D011719:Pyrazines; D050053:TRPM Cation Channels; C425966:TRPM8 protein, human; D008610:Menthol; D000069286:Bortezomib